IMPAKT 2017: New Therapies on Horizons for Breast Cancer

Speaker: Veronique Dieras

Veronique Dieras reports exciting results from a recent trial about CDK4-6 inhibitors in ER+ metastatic breast cancer. These findings suggest opportunities for both metastatic and early stage, and ongoing clinical trial already show promising data. 

These findings suggest opportunities for both metastatic and early stage, and ongoing clinical trial already show promising data. These new therapies may have a major impact in the future as ER+ represent over 70% of all breast cancer patients. Breast cancer being an heterogenous disease even inside subgroups such as ER+, HER2+ or triple negative, we still need biomarkers studies to be able to propose the best possible treatment to the patients. 

Discussion Points

  • Which therapeutic has recently emerged into management of breast cancer
  • Describe rapidly evolving research areas relevant for breast cancer care
  • Which agents/therapy approaches are on horizon?
  • What is the potential of these therapeutics to change the clinical care in breast cancer?